Lexaria Bioscience (LEXX) Updates Current GLP-1 Market

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Lexaria Bioscience (LEXX) Updates Current GLP-1 Market

Lexaria Updates Current GLP-1 Market

October 8, 2024 9:20 AM EDT

Kelowna, British Columbia, Oct 8, 2024 - (NewMediaWire) - - Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.

In 2020 the total market size for GLP-1 drugs was less than $4 billion. That same year, Novo Nordisk(R) paid $1.8 billion to purchase Emisphere's(R) SNAC drug delivery technology which was subsequently incorporated into Rybelsus(R) semaglutide oral tablets, resulting in the first and only Food and Drug Administration ("FDA") approved GLP-1 drug for use as an oral tablet.

Today,... More